Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Marietta, Georgia 30060


Purpose:

This is a study to evaluate a new medication dosed once a week in the treatment of bacterial infections in the blood from intravenous catheters (CR-BSI). The primary objective is to evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI relative to a standard of care treatment, vancomycin.


Criteria:

- The patient or his/her legally authorized representative has given informed consent by means approved by the investigator’s IRB/EC; - > 18 years of age; - Had one or more central venous catheters at the time initial signs of infection were evident; - Creatinine clearance <50 mL/min; - Bilirubin > 2x the upper limit of normal; - Treatment with an antibiotic effective against Gram-positive bacterial infections for more than 24 hours within 48 hours of study medication initiation, - Prolonged antibiotic therapy for CR-BSI anticipated (i.e., >2 weeks)


NCT ID:

NCT00057369


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Marietta, Georgia 30060
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 16, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.